Real-world data shows Kalydeco reduces CF-related hospitalizations

In a paper published in Health Affairs, researchers at the Cystic Fibrosis Foundation and colleagues analyzed real-world evidence and found that cystic fibrosis drug Kalydeco ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reduced CF-related hospitalizations

Read the full 344 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE